National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, United States.
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, United States.
Vaccine. 2019 Sep 3;37(37):5509-5512. doi: 10.1016/j.vaccine.2019.08.002. Epub 2019 Aug 7.
Zoster vaccine live (ZVL [Zostavax]) has been recommended for the prevention of herpes zoster (HZ) among immunocompetent adults ≥60 years in the United States since 2008. To examine changes in healthcare providers' perceptions and practices related to HZ disease and vaccination, we administered surveys to national networks of primary care physicians in 2005, 2008, and 2016. Ten years after ZVL was first licensed, physicians were more likely to respond that they perceived HZ as a serious disease and more strongly recommended ZVL, and were less likely to report less likely to report several major barriers to HZ vaccination such as patient cost, vaccine effectiveness and competing medical concerns. Overall, physician attitudes appear to be more favorable towards zoster vaccination after a decade of availability of a HZ vaccine. The new recombinant zoster vaccine (RZV [Shingrix]) may benefit from physician's increased perception of the importance of HZ and HZ vaccination.
带状疱疹疫苗（ZVL [Zostavax]）自 2008 年以来，已被推荐用于预防免疫功能正常的成年人≥60 岁的带状疱疹（HZ）在美国。为了研究与 HZ 疾病和疫苗接种相关的医疗保健提供者的观念和实践的变化，我们于 2005 年、2008 年和 2016 年对全国初级保健医生网络进行了调查。在 ZVL 首次获得许可的十年后，医生更有可能认为 HZ 是一种严重的疾病，并强烈推荐 ZVL，而不太可能报告一些 HZ 疫苗接种的主要障碍，如患者费用、疫苗效力和竞争医疗问题。总的来说，在 HZ 疫苗上市十年后，医生对带状疱疹疫苗的态度似乎更加有利。新型重组带状疱疹疫苗（RZV [Shingrix]）可能受益于医生对 HZ 和 HZ 疫苗接种重要性的认识增加。
